Compare CSW & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | ICUI |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | CSW | ICUI |
|---|---|---|
| Price | $319.45 | $153.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $314.75 | $179.50 |
| AVG Volume (30 Days) | 146.4K | ★ 217.4K |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | ★ 15.78 | N/A |
| EPS | ★ 8.52 | N/A |
| Revenue | $964,795,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $25.92 | N/A |
| Revenue Next Year | $16.37 | N/A |
| P/E Ratio | $38.84 | ★ N/A |
| Revenue Growth | ★ 14.87 | N/A |
| 52 Week Low | $230.45 | $107.00 |
| 52 Week High | $401.02 | $175.51 |
| Indicator | CSW | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 56.57 | 58.58 |
| Support Level | $317.39 | $146.33 |
| Resistance Level | $333.99 | $157.91 |
| Average True Range (ATR) | 11.27 | 5.21 |
| MACD | 0.01 | 0.41 |
| Stochastic Oscillator | 62.23 | 76.51 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.